Funding Opportunity RFA-AG-20-032 from the NIH Guide for Grants and Contracts. NIA's MD-PhD Training Program in Alzheimer's Disease and Its Related Dementias and the Behavioral and Social Sciences is designed to help strengthen the pipeline of physician-scientist leaders dedicated to using social and behavioral science approaches to addressing the nation's challenges posed by Alzheimer's disease and its related dementias (AD/ADRD). This FOA provides support to eligible domestic institutions to develop and implement effective approaches to integrated dual-degree training leading to the award of both an MD and a research doctorate degree (PhD or equivalent, e.g. DSW).

Funding Opportunity RFA-HD-20-021 from the NIH Guide for Grants and Contracts. The purpose of this RFA is to encourage studies on reproductive health, fertility and fertility preservation/treatment options in patients born with a serious chronic condition who can now expect to survive into adulthood healthy enough to consider their reproductive health and fertility options. The underlying pathophysiology of diseases such as sickle cell anemia, thalassemia, and cystic fibrosis, among others, and/or the cumulative effects of their treatment, can compromise reproductive health. This RFA encourages teams of scientists with expertise in the realm of the particular disease and in reproductive health and fertility to work together to understand the effects of the diseases and/or their treatments on parameters of reproductive health, and to identify ways to preserve, protect, or treat and reproductive deficits in these patients.

Funding Opportunity RFA-HD-20-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to increase the impact of NICHD-funded research within the scientific mission of the NICHD Population Dynamics Branch (PDB) by providing research infrastructure to: promote data sharing; support the development of procedures and technologies for data sharing; disseminate best practices in data sharing; provide a resource that catalogs NICHD-funded data available for secondary analysis; and promote the secondary analysis of data collected through NICHD grants to research teams outside the original grantees.

Funding Opportunity RFA-DA-20-010 from the NIH Guide for Grants and Contracts. There are two main purposes of the Rat Opioid Genome Project. The first is to tease out genetic, genomic, and molecular (epi)genetic variants that underlie phenotypes associated with distinct stages along the opioid use disorder (OUD) trajectory to identify potential targets for future interventions at early stages along the trajectory. The second is to identify genetic, genomic, and molecular (epi)genetic variants underlying comorbid conditions and/or phenotypes that can be used to develop therapeutics to save lives of people who are at the end stages of the OUD trajectory.

Funding Opportunity PAR-19-375 from the NIH Guide for Grants and Contracts. The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed

Funding Opportunity RFA-CA-19-064 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to reduce the burden of cancer and improve the quality of cancer care in rural areas among low-income and/or underserved populations. The FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. Specifically, the focus for observational studies (with pilot testing) is understanding and addressing the predictive and/or mediating role of social determinants of health, barriers to care, and treatment; and the focus for interventional research is on addressing quality of care related to cancer diagnosis, treatment and/or survivorship. Most existing cancer control interventions are not ready for direct implementation and dissemination in low-income rural areas, so proposals should seek to develop, adapt, and/or implement, and test interventions.

Funding Opportunity RFA-OD-19-027 from the NIH Guide for Grants and Contracts. The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing or improving animal models of human diseases; improving access to information about or generated from the use of animal models of human disease; or improving diagnosis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIPs trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad research areas supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of research will not be considered acceptable. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA.

Notice NOT-EB-19-020 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-075 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-20-045 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R61/12/R33 applications to develop interventions for physician compliance with recommended prevention guidelines for the elderly from the Centers for Disease Control and Prevention (CDC) and the US Preventive Services Task Force (USPTF). Specifically, applicants will develop electronic health record (EHR)-based interventions to improve the quality of care and health outcomes, and reduce health disparities. This FOA will support an R261 pilot phase, which will allow researchers to use data analytics tools, including machine learning approaches, to establish the feasibility of identifying groups of patients not receiving recommended preventive care, and then create scalable, tailored interventions for these groups to help overcome barriers to uptake. If successful, researchers may transition to an R33 phase for implementation of pragmatic trials. All applicants are required to address health disparities.

Notice NOT-OD-19-141 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-143 from the NIH Guide for Grants and Contracts

DOE: Dana-Farber Cancer Institute: Postdoctoral Postion in Gabuzda Laboratory at DFCI Boston, Massachusetts (US)

Competitive Salary: EMBL: Project Leader - Model Organism Genomics Location: Cambridge, Cambridgeshire, England

Funding Opportunity RFA-CA-19-056 from the NIH Guide for Grants and Contracts. The purpose of the proposed Funding Opportunity Announcement (FOA) is to continue support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: 1) Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. The AMC must consist of the following functional units: a Coordination Center, Clinical Trial Sites, Network Laboratories, and a Statistical Center. The AMC team must have at least four scientific disease-oriented Working Groups to study Kaposi Sarcoma, Lymphoma, Human papilloma virus-associated cancers, and non-AIDS-Defining cancers. The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions. All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.

Funding Opportunity RFA-AI-19-063 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release (SER) drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA focuses on the following scientific priority DDS: low-volume, self-injectable depots, erosible/biodegradable implants including in situ forming implants, intrauterine delivery systems and transdermal delivery systems. Applications will require an industry partner. Applications incorporating drugs that are already under development or approved for HIV prevention and/or treatment by their intellectual property/patent/license holder must involve these persons/entities in a meaningful and significant manner in the application through letters of support and/or other evidence of a substantial commitment.

Funding Opportunity PAR-19-372 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and health disparity populations.

Notice NOT-DK-19-025 from the NIH Guide for Grants and Contracts

Notice NOT-AA-19-025 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-026 from the NIH Guide for Grants and Contracts